UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

Cancer, 2024-10, Vol.130 (20), p.3436-3451

2024

Volltextzugriff (PDF)

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Leukemia, 2021-06, Vol.35 (6), p.1571-1585

2021

Volltextzugriff (PDF)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

Scientific reports, 2021-10, Vol.11 (1), p.20745-20745, Article 20745

2021

Volltextzugriff (PDF)

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Haematologica (Roma), 2024-01, Vol.109 (1), p.115

2024

Volltextzugriff (PDF)

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Blood, 2001-09, Vol.98 (6), p.1746-1751

2001

Volltextzugriff (PDF)

Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.132-132, Article 132

2023

Volltextzugriff (PDF)

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia

Cancers, 2022-06, Vol.14 (11), p.2817

2022

Volltextzugriff (PDF)

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

Leukemia research, 2009-12, Vol.33 (12), p.1706-1709

2009

Volltextzugriff (PDF)

Minimal residual disease monitoring by flow cytometry

Best practice & research. Clinical haematology, 2003-12, Vol.16 (4), p.599-612

2003

Volltextzugriff (PDF)

No Differences in Levels of Circulating Progenitor Endothelial Cells or Circulating Endothelial Cells Among Patients Treated With Ticagrelor Compared With Clopidogrel During Non- ST -Segment-Elevation Myocardial Infarction

Journal of the American Heart Association, 2018-10, Vol.7 (19), p.e009444-e009444

2018

Volltextzugriff (PDF)

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)

Best practice & research. Clinical haematology, 2002-03, Vol.15 (1), p.105-118

2002

Volltextzugriff (PDF)

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Investigational new drugs, 2012-06, Vol.30 (3), p.1121-1131

2012

Volltextzugriff (PDF)

Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Haematologica (Roma), 2023-05

2023

Volltextzugriff (PDF)

Interleukin-6 Promotes Multiple Myeloma Cell Growth Via Phosphorylation of Retinoblastoma Protein

Blood, 1996-09, Vol.88 (6), p.2219-2227

1996

Volltextzugriff (PDF)

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML)

Blood, 2007-11, Vol.110 (11), p.1850-1850

2007

Volltextzugriff (PDF)

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML): Minimal Residual Disease Investigation in Haematological Malignancies

Best practice & research. Clinical haematology, 2002, Vol.15 (1), p.105-118

2002

Volltextzugriff (PDF)

Minimal residual disease monitoring by flow cytometry: Immunophenotyping in leukemia and lymphoma

Best practice & research. Clinical haematology, 2003, Vol.16 (4), p.599-612

2003

Volltextzugriff (PDF)

Transforming Growth Factor-β1: Differential Effects on Multiple Myeloma Versus Normal B Cells

Blood, 1996-03, Vol.87 (5), p.1928-1938

1996

Volltextzugriff (PDF)

Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies

Molecular Medicine Today, 1996-10, Vol.2 (10), p.425-431

1996

Volltextzugriff (PDF)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

British journal of haematology, 2015-11, Vol.171 (3), p.344-354

2015

Volltextzugriff (PDF)

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients

Haematologica (Roma), 2009-11, Vol.94 (11), p.1599-1602

2009

Volltextzugriff (PDF)

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

Haematologica (Roma), 2010-01, Vol.95 (1), p.87-95

2010

Volltextzugriff (PDF)

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

Haematologica (Roma), 2015-02, Vol.100 (2), p.e53-e55

2015

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(40)
Buchkapitel
(1)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Hematology
(25)
Aged
(21)
Female
(20)
Male
(20)
Middle Aged
(19)
Adult
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Hematologic And Hematopoietic Diseases
(14)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(13)
Prognosis
(13)
Flow Cytometry
(11)
Acute Myeloid Leukemia
(9)
Aged, 80 And Over
(9)
Immunophenotyping
(9)
Adolescent
(8)
Oncology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Haematologica
(13)
Blood
(9)
Best Practice & Research. Clinical Haematology
(4)
Blood Cancer Journal
(2)
British Journal Of Haematology
(2)
Br J Haematol
(1)
Cancer
(1)
Cancers
(1)
Clinical Cancer Research
(1)
Clinical Lymphoma
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

Minimal residual disease monitoring by flow cytometry

No Differences in Levels of Circulating Progenitor Endothelial Cells or Circulating Endothelial Cells Among Patients Treated With Ticagrelor Compared With Clopidogrel During Non- ST -Segment-Elevation Myocardial Infarction

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Interleukin-6 Promotes Multiple Myeloma Cell Growth Via Phosphorylation of Retinoblastoma Protein

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML)

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML): Minimal Residual Disease Investigation in Haematological Malignancies

Minimal residual disease monitoring by flow cytometry: Immunophenotyping in leukemia and lymphoma

Transforming Growth Factor-β1: Differential Effects on Multiple Myeloma Versus Normal B Cells

Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

Suchergebnisse filtern